FindTrial
Sign In

Role of Bromocriptine in Peripartum Cardiomyopathy

Role of Bromocriptine in Peripartum Cardiomyopathy: A Randomized Controlled Study in a Tertiary Care Centre of North India

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057654
Enrollment
84
Registered
2023-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O268- Other specified pregnancy relatedconditions

Interventions

Intervention1: Treatment: Tab bromocriptine 5 mg will be given for 2 weeks followed by 2.5 mg for 6 weeks Control Intervention1: Not applicable: Not applicable

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women who will be diagnosed as having PPCM with ejection fraction =35%

Exclusion criteria

Exclusion criteria: Clinical conditions other than cardiomyopathy that could increase plasma levels of inflammatory markers such as sepsis, autoimmune disease, or HIV positivity Any thrombogenic condition Severe peptic ulcer disease

Design outcomes

Secondary

MeasureTime frame
Levels of prolactin and cardiac biomarkers Growth patterns of the infantsTimepoint: 8 weeks and 6 months—

Primary

MeasureTime frame
Improvement in ejection fraction Full recovery (ejection fraction =50%) Timepoint: Improvement in ejection fraction at 8 weeks Full recovery (ejection fraction =50%) at 6 months—

Countries

India

Contacts

Public ContactDR Jyotsna Suri

VMMC and Safdarjung Hospital

jyotsnasuri@gmail.com9810858358

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026